Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis
- PMID: 16081646
- DOI: 10.1210/en.2005-0239
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis
Abstract
Both chronic excess of PTH, as in hyperparathyroidism, and intermittent elevation of PTH (by daily injections) increase the number of osteoblasts; albeit, the former is associated with bone catabolism and the later with bone anabolism. Intermittent PTH increases osteoblast number by attenuating osteoblast apoptosis, an effect that requires the transcription factor Runx2. However, chronic elevation of PTH does not affect osteoblast apoptosis because it stimulates the proteasomal degradation of Runx2. Here, we studied the effects of PTH on Sost, a Runx2 target gene expressed in osteocytes (former osteoblasts embedded in the bone matrix), which antagonizes the pro-osteoblastogenic actions of bone morphogenetic proteins and Wnts. We report that continuous infusion of PTH to mice for 4 d decreased Sost mRNA expression in vertebral bone by 80-90%. This effect was accompanied by a comparable reduction of sclerostin, the product of Sost, in osteocytes, as determined by quantitative immunoblot analysis of bone extracts and by immunostaining. In contrast, a single injection of PTH caused a transient 50% reduction in Sost mRNA at 2 h, but four daily injections had no effect on Sost mRNA or sclerostin. PTH strongly decreased Sost expression in osteocytes formed in primary cultures of neonatal murine calvaria cells as well as in osteocytic MLO-A5 cells, demonstrating a direct effect of PTH on this cell type. These results, together with evidence that sclerostin antagonizes bone morphogenetic proteins and Wnts, strongly suggest that suppression of Sost by PTH represents a novel mechanism for hormonal control of osteoblastogenesis mediated by osteocytes.
Similar articles
-
Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone.J Mol Histol. 2007 Aug;38(4):261-9. doi: 10.1007/s10735-007-9096-3. Epub 2007 Jun 5. J Mol Histol. 2007. PMID: 17549589
-
SOST is a target gene for PTH in bone.Bone. 2005 Aug;37(2):148-58. doi: 10.1016/j.bone.2005.03.018. Bone. 2005. PMID: 15946907
-
Does osteocytic SOST suppression mediate PTH bone anabolism?Trends Endocrinol Metab. 2010 Apr;21(4):237-44. doi: 10.1016/j.tem.2009.12.002. Epub 2010 Jan 13. Trends Endocrinol Metab. 2010. PMID: 20074973 Review.
-
Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes.J Musculoskelet Neuronal Interact. 2006 Oct-Dec;6(4):358-9. J Musculoskelet Neuronal Interact. 2006. PMID: 17185824 No abstract available.
-
[Biological function of bone cells on the PTH-driven anabolic effect].Clin Calcium. 2012 Mar;22(3):373-9. Clin Calcium. 2012. PMID: 22370304 Review. Japanese.
Cited by
-
Effect of Qing'e formula on circulating sclerostin levels in patients with postmenopausal osteoporosis.J Huazhong Univ Sci Technolog Med Sci. 2015 Aug;35(4):525-530. doi: 10.1007/s11596-015-1464-8. Epub 2015 Jul 31. J Huazhong Univ Sci Technolog Med Sci. 2015. PMID: 26223921
-
Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin.J Bone Miner Res. 2016 Oct;31(10):1791-1802. doi: 10.1002/jbmr.2869. Epub 2016 Jun 5. J Bone Miner Res. 2016. PMID: 27163932 Free PMC article.
-
Sclerostin and CKD-MBD.Curr Osteoporos Rep. 2015 Jun;13(3):159-65. doi: 10.1007/s11914-015-0263-2. Curr Osteoporos Rep. 2015. PMID: 25691219 Review.
-
Bone turnover in hyperparathyroidism.Wien Med Wochenschr. 2013 Sep;163(17-18):391-6. doi: 10.1007/s10354-012-0125-9. Epub 2012 Jul 18. Wien Med Wochenschr. 2013. PMID: 22805761 Review.
-
The osteocytic actions of glucocorticoids on bone mass, mechanical properties, or perilacunar remodeling outcomes are not rescued by PTH(1-34).Front Endocrinol (Lausanne). 2024 Jul 18;15:1342938. doi: 10.3389/fendo.2024.1342938. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39092287 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources